SENSEX 77414.92 ▼ (0.25%)
BSE BANKEX 59542.38 ▲ (0.36%)

LUPIN

BSE: 500257 09 Sep 2025
Healthcare
₹ 1937.1
Lupin Ltd specializes in Pharmaceuticals within the Healthcare sector.

LUPIN - Share Price & Details

Market Cap
₹88,738
High /Low
2,403 / 1,774
Stock P/E
24.0
Book Value
₹377.0
Dividend Yield
0.62
ROCE
21.3
ROE
₹20.6
Face Value
2.0
PEG Ratio
0.4
EVEBITDA
₹15.2
Debt
5,448
CMP / FCF
59.0
Debt to equity
₹0.32
NP Ann
3,306
High price all time
2,403
Piotroski score
₹6.0
Graham Number
829.0
No. Eq. Shares
45.7
Net CF
₹560
Net profit
3,722
Price to book value
5.16
Interest Coverage
₹14.9
Low price all time
52.5
Industry PE
33.4
Reserves
₹17,112
Free Cash Flow
₹1,347

Price Chart


Volume Chart


Peer Comparison

Stock Total Income Net Profit Net Sales EPS Market Cap (in Cr) P/E
FABINO ENTERPRISES LIMITEDNANANANA5.4691.0
Triochem Products Ltd.,NANANANA0
LUPIN LTD.57627.321280.757085.946.4888,73824.0
FORTIS HEALTHCARE LTD.4730.4518.84330.30.697155977.8
ABBOTT INDIA LTD.NANANANA6588845.4

Peer Comparison Chart


About LUPIN

Lupin Ltd, with Security Code 500257, is a leading player in the Pharmaceuticals industry, categorized under the Healthcare sector, offering Equity instruments.


Latest News

Now Sun Pharma, Lupin work on anti-obesity pill to cut costs, address jab aversion | Company Business News

(08 Sep 2025)
Sun Pharma and Lupin pursue regulatory approval for oral weight-loss drugs, potentially reshaping treatment access.
Read more →

Sun Pharma, Lupin push for affordable anti-obesity pills in India - Mint

(08 Sep 2025)
Investing.com-- India's Sun Pharmaceutical Industries (NSE:SUN) and Lupin Ltd (NSE:LUPN) are seeking regulatory approval to develop...
Read more →

Stock Alert: Adani Power, Lupin, Dr Reddy's Laboratories, Imagicaaworld Entertainment, Kaynes Technology India

(08 Sep 2025)
RBL Bank shares are banned from F&O trading on 8 September 2025. Result Today: R M Drip Sprinklers Systems, Cedaar Textile and Housing...
Read more →

lupin has received approval from usfda for its anda for risperidone

(05 Sep 2025)
News: Lupin has received approval from USFDA for its ANDA for Risperidone 25 mg, 37.5 mg and 50 mg vial, Single dose Vial. This is Lupin's first product...
Read more →

Lupin Ltd. Shows Signs of Trend Reversal Amid Market Dynamics in Pharmaceuticals Sector

(04 Sep 2025)
Lupin Ltd. experienced a notable performance on September 3, 2025, following a six-day decline. The stock outperformed the broader market,...
Read more →

Lupin Secures USFDA Approval for Innovative Injectable Schizophrenia Treatment

(04 Sep 2025)
Lupin Ltd has gained USFDA approval for its generic risperidone injectable suspension, used for schizophrenia and bipolar disorder in adults...
Read more →

Company Updates